亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Chimeric Antigen Receptors For Phagocytosis (Car-P)

技術優勢

Approximately 143,000 new cases of leukemia and lymphoma will be diagnosed in the US in 2018, with about 44,000 patients dying from these diseases in this year. Current standards of treatment are chemotherapy and stem cell transplantation, but recently CAR-T therapies that utilize engineered T cells such as Kymriah and Yescarta have become available to treat some rare and persistent forms of leukemia. In addition to being effective in cases where traditional therapies have failed, these CAR-T therapies are promising due to their shorter duration of treatment and long-term efficacy over traditional treatments.However, since T cells cannot readily penetrate solid tumors, these CAR-T therapies are unlikely to be effective in some forms of lymphoma. Macrophages however readily interact with the tumor microenvironment of solid tumors. CAR-P therapies therefore could help bypass this hurdle and provide additional treatment options that can work either alone or with existing treatments to improve patient survival. ADVANTAGES OF TECHNOLOGY Utilizes a synthetic receptor to direct innate immune system to attack cancer through phagocytosisMacrophages can more effectively interact within the tumor microenvironment of solid lymphomas than T cells.Cross presentation in macrophages and dendritic cells can increase the number of cancer antigen specific T cells rather than the single predefined antigen in traditional CAR-T therapies.Co-culture of CAR-P macrophages and cancer cells drives a significant reduction in the number of cancer cells

詳細技術說明

Chimeric Antigen Receptors for Phagocytosis (CAR-P) consist of an extracellular antibody fragment specific against cancer antigens, a plasma membrane signal peptide and transmembrane domain, and the cytoplasmic domains of an engulfment receptor. When expressed in macrophages, the extracellular antibody fragment recognizes and binds to specific cancer antigens. This leads to the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs), which promotes either partial or whole cell phagocytosis of the bound target cell.

其他

Stage of Development

Pre-clinical

Looking for Partners

To develop & commercialize the technology for cancer therapeutics

Data Availability

See publication. Further information under CDA / NDA

Related Materials

Morrissey MA, Wiliamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, Vale RD. “Chimeric antigen receptors that trigger phagocytosis” eLife (2018).

Additional Technologies by these Inventors